Výsledky vyhledávání - "Karin, Beelen"

Akademický článek

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Autor: Karin Beelen, Mark Opdam, Tesa Severson, Rutger Koornstra, Andrew Vincent, Jelle Wesseling, Joyce Sanders, Jan Vermorken, Paul van Diest, Sabine Linn

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)

Abstract Background Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic

Externí odkaz: https://doaj.org/article/c558154a46ac40b6b7bc562fdd869e71

Zobrazit plný text záznamu

Plný text ve formátu HTML

Figure S2 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Pharmacokinetics: Z-endoxifen levels per taselisib dose level

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b8c3ce186a1e98a096fd80e837ef085
https://doi.org/10.1158/1078-0432.22471986.v1

Zobrazit plný text záznamu

Data from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Purpose:The strategy of combining endocrine therapy with PI3K-mTOR inhibition has shown promise in estrogen receptor (ER)–positive breast cancer, but new agents and combinations with a better therapeutic index are urgently needed. Taselisib is a po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38dbcd046b3ffe289c7694d6875e0bdd
https://doi.org/10.1158/1078-0432.c.6528075

Zobrazit plný text záznamu

Supplementary Methods from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Supplementary Methods Text

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1182c2cadec2b5dc324fec46d078953
https://doi.org/10.1158/1078-0432.22471977.v1

Zobrazit plný text záznamu

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group

Autor: S.P. Gampenrieder, V. Dezentjé, M. Lambertini, A. de Nonneville, M. Marhold, F. Le Du, A. Cortés Salgado, D. Alpuim Costa, M. Vaz Batista, N. Chic Ruché, C. Tinchon, A. Petzer, E. Blondeaux, L. Del Mastro, G. Targato, F. Bertucci, A. Gonçalves, F. Viret, R. Bartsch, C. Mannsbart, A. Deleuze, L. Robert, C. Saavedra Serrano, M. Gion Cortés, M. Sampaio-Alves, M. Vitorino, L. Pecen, C. Singer, N. Harbeck, G. Rinnerthaler, R. Greil, Marija Balic, Sonja Heibl, August Felix Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christopher Hager, Michael Knauer, Michael Hubalek, Claudia Bighin, Michelino De Laurentiis, Sabino De Placido, Fabio Puglisi, Luca Boni, Amelie de Gregorio, Tom Degenhardt, Luigi Formisano, Karin Beelen, Timothy Robinson, Amanda Fitzpatrick, Veronique Dieras, Volkmar Muller, Alessandra Gennari, Sabine Linn, Sofia Braga, Javier Cortes, Carlo Palmieri

Publikováno v: ESMO open. 8(1)

Funding Information: This project was initiated at the Endeavour Breast Project coordinated by Daiichi Sankyo (special thanks to Christian Opitz and Britta Mazur from Daiichi Sankyo). We thank all participants and the steering committee members of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6a2cfd454951606b7db15bc6bb3b4b0
https://pubmed.ncbi.nlm.nih.gov/36563519

Zobrazit plný text záznamu

PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane

Autor: Dinja T. Kruger, Karin Beelen, Vincent van der Noort, Sabine C. Linn, Joyce Sanders, Epie Boven, Mark Opdam, Bart de Valk, Michiel Nieuwenhuis

Publikováno v: Journal of Cancer Research and Clinical Oncology
Kruger, D T, Opdam, M, van der Noort, V, Sanders, J, Nieuwenhuis, M, de Valk, B, Beelen, K J, Linn, S C & Boven, E 2020, ' PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane ', Journal of Cancer Research and Clinical Oncology, vol. 146, no. 11, pp. 3013-3023 . https://doi.org/10.1007/s00432-020-03291-x
Journal of Cancer Research and Clinical Oncology, 146(11), 3013-3023. Springer Verlag

Purpose Everolimus plus exemestane (EVE/EXE) is a registered treatment option for ER-positive, HER2-negative (ER +/HER2-) metastatic breast cancer (MBC), but resistance mechanisms limit efficacy. We aimed to find markers that might help select patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9a57315afaf23040348c87692a37d13
http://www.scopus.com/inward/record.url?scp=85086852955&partnerID=8YFLogxK

Zobrazit plný text záznamu

Abstract P6-17-19: What to do with trastuzumab therapy after achieving radiological complete remission (rCR) in HER2+ metastatic breast cancer (MBC)?

Autor: P. C. De Jong, Joyce Sanders, Nathalie I. Bouwer, A. J. Ten Tije, Karin Beelen, Hugo M. Horlings, Hánah N. Rier, Carolien H. Smorenburg, GS Sonke, M-D Levin, C Holterhues, Jan C. Drooger, Agnes Jager, Tessa G Steenbruggen

Publikováno v: Cancer Research. 79:P6-17

Intro MBC is generally considered incurable, but patients with HER2+ disease treated with trastuzumab do relatively well and some have an exceptional durable response and survive over 10 years. We analyzed the clinical-pathological characteristics as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c1167ccd666758c80fb23443c03d528
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-19

Zobrazit plný text záznamu

POSEIDON trial phase 1B results: Safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients

Publikováno v: Clinical cancer research, 25(22), 6598-6605. American Association for Cancer Research Inc.
Clinical Cancer Research, 25(22), 6598. American Association for Cancer Research Inc.

Purpose: The strategy of combining endocrine therapy with PI3K-mTOR inhibition has shown promise in estrogen receptor (ER)–positive breast cancer, but new agents and combinations with a better therapeutic index are urgently needed. Taselisib is a p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f6f4bdf552aa7b4f6e72d8741c006c
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075060360&origin=inward

Zobrazit plný text záznamu

LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)

Autor: Mariette Schrier, D. López-García, A.G.J. van Rossum, Carlos Caldas, A. Kateb, C. Saura Manich, R. A. B. Voorthuis, C. Mather, S. Muñoz, Karin Beelen, L. Garrigos Cubells, I.A.M. Mandjes, Sabine C. Linn, J. Cortés, Karolina Sikorska, Mafalda Oliveira, L. De Boo, Margaret Schot, R. D. Baird

Publikováno v: Annals of Oncology. 32:S1291-S1292

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::244f52c1b35b4f9d06566a35b78e6ba0
https://doi.org/10.1016/j.annonc.2021.08.2091

Zobrazit plný text záznamu

‘Dure medicijnen vormen een weerbarstig en ingewikkeld dossier’

Autor: Rob de Rijke, Karin Beelen, Erik Meijer

Publikováno v: Fizier. 35:10-13

Het verstrekken van steeds duurdere medicijn stelt ziekenhuizen voor dilemma’s. Fizier ging daarover in gesprek met de apotheker, een oncoloog en een financial van het Reinier de Graaf Gasthuis in Delft. ‘Sommigen vinden de discussie niet ethisch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bcd14268d0bafa8275bba3de2b269191
https://doi.org/10.1007/s40739-018-0015-3

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání